Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVONEST vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Emergency contraception (FDA-approved),Contraception (as a progestin-only pill or in combination with estrogen),Off-label: treatment of menorrhagia, endometriosis, and as a component of hormone replacement therapy
Prevention of pregnancy (FDA-approved)
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Primarily hepatic via CYP3A4; undergoes reduction and conjugation; excreted in urine and feces.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Levonorgestrel is extensively bound to sex hormone-binding globulin (SHBG) and albumin; approximately 97-99% bound, with the free fraction being pharmacologically active.
~99% bound to serum albumin and sex hormone-binding globulin.
Apparent volume of distribution is about 1.8 L/kg, indicating extensive distribution into tissues beyond plasma water.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral bioavailability is approximately 100% due to minimal first-pass metabolism; levonorgestrel is completely absorbed after oral administration.
Oral: ~70% due to first-pass metabolism.
No dosage adjustment required for any degree of renal impairment.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, no specific dose adjustment available; use with caution.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Weight ≥ 75 kg: single dose of levonorgestrel 1.5 mg orally. Weight < 75 kg: single dose of 1.5 mg is also used, but efficacy may be reduced; consider alternative methods.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women; no specific dose adjustment established for elderly.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
None.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Do not use as regular contraceptive if multiple doses are taken in one cycle,Ectopic pregnancy risk reduced but not eliminated,Menstrual irregularities,Rare cases of hepatic adenoma or thromboembolic events,Use with caution in patients with severe hepatic impairment or malabsorption syndromes
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy,Hypersensitivity to levonorgestrel or any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No clinically significant food interactions. Levonest releases levonorgestrel locally in the uterus, and systemic absorption is minimal. No dietary restrictions required.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
LEVONEST (levonorgestrel) is associated with minimal teratogenic risk if inadvertently used during pregnancy. First trimester: No increased risk of major malformations based on epidemiologic data. Second/third trimester: No known adverse fetal effects from occasional use; no evidence of fetotoxicity or teratogenicity from clinical studies. However, as a progestin-only contraceptive, it is not indicated during pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Levonorgestrel is excreted into breast milk in small amounts (estimated infant dose <0.1% of maternal dose). M/P ratio not established. No adverse effects reported in breastfed infants with short-term use. The WHO considers it compatible with breastfeeding. Caution with prolonged use may reduce milk supply.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dosing adjustments are applicable as LEVONEST is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy do not require dose modifications because the drug should not be used during pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Levonest (levonorgestrel-releasing intrauterine system) provides effective contraception for up to 5 years. It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. May reduce menstrual bleeding and dysmenorrhea. Expulsion risk is highest in first year, especially right after insertion. Check strings after each period. Contraindicated in acute pelvic inflammatory disease, postpartum endometritis, infected abortion, or untreated cervical infection.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Levonest is a small T-shaped device placed in your uterus that releases a hormone to prevent pregnancy for up to 5 years.,You may have irregular bleeding or spotting for the first 3-6 months, which typically decreases over time.,Check the strings at the end of your period each month to ensure the device is in place.,Do not use Levonest if you think you might be pregnant, have a current pelvic infection, or have certain uterine abnormalities.,Most women can use Levonest safely; serious complications are rare but include perforation, expulsion, and infection.,Seek medical attention if you experience severe abdominal pain, fever, heavy bleeding, or missing strings.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVONEST vs AFIRMELLE, answered by our medical review team.
LEVONEST is a Oral Contraceptive that works by Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVONEST and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVONEST is: One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVONEST and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVONEST is classified as Category C. LEVONEST (levonorgestrel) is associated with minimal teratogenic risk if inadvertently used during pregnancy. First trimester: No increased risk of major malformations based on epi. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.